Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11899-014-0220-7 http://scihub22266oqcxt.onion/10.1007/s11899-014-0220-7 C4909353!4909353!24942298     free     free     free       Curr+Hematol+Malig+Rep 2014 ; 9 (3): 284-93 Nephropedia Template TP {{tp|p=24942298|t=2014. Relapsed Hodgkin Lymphoma: Management Strategies |pdf=|usr=}}{{24942298}} gab.com Text Relapsed Hodgkin Lymphoma: Management Strategies JO: Curr Hematol Malig Rep http://www.kidney.de/pget.php?&tw=1&pmid=24942298 #FOAvip Although Hodgkin lymphoma (HL) is largely curable with first-line therapy, approximately one-third of patients will not have a complete response to frontline treatment or will subsequently relapse. Only 50 % of these patients will be effectively salvaged with conventional therapies. The prognosis is particularly poor for those patients with chemotherapy refractory disease, who are unable to obtain even transient disease control, and for patients who relapse following high dose chemotherapy and autologous stem cell transplant. In this review, we summarize the most recent updates on the management of patients with relapsed HL, the role of novel therapies such as brentuximab vedotin, and an overview of promising new agents currently under investigation. We also discuss the role of consolidation strategies such as high-dose chemotherapy and autologous stem cell transplant, and reduced-intensity allogeneic hematopoietic stem cell transplant, and the need for new strategies in the elderly patient population. Twit Text FOAVip Relapsed Hodgkin Lymphoma: Management Strategies ????Curr Hematol Malig Rep http://www.kidney.de/pget.php?&tw=1&pmid=24942298 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24942298 #FOAvip English Wikipedia <ref>{{Cite pmid|24942298}}</ref> Relapsed Hodgkin Lymphoma: Management Strategies #MMPMID24942298 Montanari F; Diefenbach C Curr Hematol Malig Rep 2014[Sep]; 9 (3): 284-93 PMID24942298show ga Although Hodgkin lymphoma (HL) is largely curable with first-line therapy, approximately one-third of patients will not have a complete response to frontline treatment or will subsequently relapse. Only 50 % of these patients will be effectively salvaged with conventional therapies. The prognosis is particularly poor for those patients with chemotherapy refractory disease, who are unable to obtain even transient disease control, and for patients who relapse following high dose chemotherapy and autologous stem cell transplant. In this review, we summarize the most recent updates on the management of patients with relapsed HL, the role of novel therapies such as brentuximab vedotin, and an overview of promising new agents currently under investigation. We also discuss the role of consolidation strategies such as high-dose chemotherapy and autologous stem cell transplant, and reduced-intensity allogeneic hematopoietic stem cell transplant, and the need for new strategies in the elderly patient population. äRelapsed Hodgkin Lymphoma: Management Strategies (epmc).pdf DeepDyve Pubget Overpricing